文档介绍：Breast Cancer Res Treat
DOI -007-9722-5
CLINICAL TRIAL
A phase II study of pemetrexed and carboplatin in patients
with locally advanced or metastatic breast cancer
August Garin Æ Alexey Manikhas Æ Mikhail Biakhov Æ Mikhail Chezhin Æ
Tatiana Ivanchenko Æ Kurt Krejcy Æ Vera Karaseva Æ Sergey Tjulandin
Received: 26 January 2007 / Accepted: 31 July 2007
Ó Springer Science+Business Media, LLC 2007
Abstract enrolled at 3 study centers. Twenty-eight percent of patients
Background Pemetrexed and carboplatin have demon- previously received adjuvant chemotherapy, % had
strated activity in breast cancer. Their potential synergism visceral metastases, and % had ans involved.
in experimental models and the proven efficacy of Partial responses (RECIST criteria) were achieved in 27
pemetrexed/platinum in other indications make pemetr- (%) patients (ORR = %; 95% CI, –%). The
exed/carboplatin an bination in breast median response duration was months (95% CI, –
cancer. Thus, this two-stage, sequential, open-label, mul- months) and the median time to disease progression
ticenter, phase II study assessed the efficacy and safety of was months (95% CI, – months). CTC hema-
pemetrexed plus carboplatin as first-line therapy in patients tologic toxicities were grade 3/4 neutropenia (%/%)
with locally advanced breast